Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients
Ian W. Flinn(Tennessee Oncology), John D. Hainsworth(Sarah Cannon), Eric Raefsky(Tennessee Oncology), Evan Lang(Oncology Hematology Care), Howard A. Burris(Deaconess Hospital), Ines Macias‐Perez(Vanderbilt University), Ralph V. Boccia(Center for Cancer and Blood Disorders)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k